The new man at the helm of Eli Lilly (NYSE: LLY) has started off his time as the US pharma major’s chief executive by announcing a series of organizational and leadership structure changes.
David Ricks is taking on the responsibility of not only replacing John Lechleiter following his nine years in charge, but also attempting to move the company on from disappointing results on solanezumab, its lead candidate for Alzheimer’s disease, in a Phase III trial.
"Lilly is in the early stages of a new growth period"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze